In response to the problems existing in the clinical use of antitumor biosimilars（AtBs）

the use of therapeutic drug monitoring（TDM） technology can help to guide and standardize the rational use of At Bs

the Chinese Pharmacological Society and China-Japan Friendship Hospital jointly initiated and formed"Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（2020 Edition） ". The consensus focuses on 8 clinical problems and makes 17 recommendations

which clarifies the necessity of TDM for At Bs in clinical treatment

key points of individualized monitoring program

technical methods and participation of clinical pharmacists

and guides pharmacists to provide practical pharmaceutical technical support to clinicians by TDM

so as to ensure the maximum benefits for patients.